FDA panel rejects Bystolic for treating heart failure

01/11/2010 | Reuters

An FDA panel recommended against approving Forest Laboratories' hypertension drug Bystolic for treating heart failure, saying clinical data were not sufficient to prove the treatment's safety. Forest President and Chief Operating Officer Larry Olanoff said the company is disappointed but will confer with the agency on possibly adding a label that conveys information about the heart failure study.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA